<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05040113</url>
  </required_header>
  <id_info>
    <org_study_id>CBP-307CN004</org_study_id>
    <nct_id>NCT05040113</nct_id>
  </id_info>
  <brief_title>A Study On Human Mass Balance And Biotransformation</brief_title>
  <official_title>A Clinical Study to Evaluate Absorption, Metabolism and Excretion of [14C] CBP-307 in Healthy Chinese Male Adult Subjects - Human Mass Balance and Biotransformation Study of [14C] CBP-307</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Suzhou Connect Biopharmaceuticals, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Suzhou Connect Biopharmaceuticals, Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the absorption,metabolism and excretion of CBP-307 in healthy&#xD;
      chinese male subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 4, 2021</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum concentration (Cmax)</measure>
    <time_frame>Pre-dose and 1hour,2hour,4hour,6hour,7hour,8hour,10hour,12hour,24hour,48hour,72hour,96hour,120hour,144hour,168hour,216hour,264hour,312hour,360hour,408hour,456hour,504hour post-dose</time_frame>
    <description>Ratio of total radioactivity in whole blood to that in plasma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative recovery of total radioactivity in urine or/and feces</measure>
    <time_frame>-24 to 0 hour predose to Day22</time_frame>
    <description>Percentage of each metabolite in urine and feces to the administered dose (% of administered dose) or percentage of circulating metabolites in plasma to total exposure AUC (% AUC)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Peak (Tmax)</measure>
    <time_frame>Pre-dose and 1hour,2hour,4hour,6hour,7hour,8hour,10hour,12hour,24hour,48hour,72hour,96hour,120hour,144hour,168hour,216hour,264hour,312hour,360hour,408hour,456hour,504hour post-dose</time_frame>
    <description>Ratio of total radioactivity in whole blood to that in plasma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve (AUC0-t and AUC0-inf)</measure>
    <time_frame>Pre-dose and 1hour,2hour,4hour,6hour,7hour,8hour,10hour,12hour,24hour,48hour,72hour,96hour,120hour,144hour,168hour,216hour,264hour,312hour,360hour,408hour,456hour,504hour post-dose</time_frame>
    <description>Ratio of total radioactivity in whole blood to that in plasma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Elimination half-life (t1/2)</measure>
    <time_frame>Pre-dose and 1hour,2hour,4hour,6hour,7hour,8hour,10hour,12hour,24hour,48hour,72hour,96hour,120hour,144hour,168hour,216hour,264hour,312hour,360hour,408hour,456hour,504hour post-dose</time_frame>
    <description>Ratio of total radioactivity in whole blood to that in plasma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Clearance (CL/F)</measure>
    <time_frame>Pre-dose and 1hour,2hour,4hour,6hour,7hour,8hour,10hour,12hour,24hour,48hour,72hour,96hour,120hour,144hour,168hour,216hour,264hour,312hour,360hour,408hour,456hour,504hour post-dose</time_frame>
    <description>Ratio of total radioactivity in whole blood to that in plasma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Volume of Distribution (Vd/F)</measure>
    <time_frame>Pre-dose and 1hour,2hour,4hour,6hour,7hour,8hour,10hour,12hour,24hour,48hour,72hour,96hour,120hour,144hour,168hour,216hour,264hour,312hour,360hour,408hour,456hour,504hour post-dose</time_frame>
    <description>Ratio of total radioactivity in whole blood to that in plasma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Residence Time (MRT)</measure>
    <time_frame>Pre-dose and 1hour,2hour,4hour,6hour,7hour,8hour,10hour,12hour,24hour,48hour,72hour,96hour,120hour,144hour,168hour,216hour,264hour,312hour,360hour,408hour,456hour,504hour post-dose</time_frame>
    <description>Ratio of total radioactivity in whole blood to that in plasma</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Healthy Adult Subjects</condition>
  <arm_group>
    <arm_group_label>CBP-307</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Take CBP-307orally at 30 min ± 2 min after the start of high-fat breakfast intake</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CBP-307</intervention_name>
    <description>CBP-307 capsules oral administration</description>
    <arm_group_label>CBP-307</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. A healthy male adult&#xD;
&#xD;
          2. Age: 18 to 45 years old (inclusive)&#xD;
&#xD;
          3. Weight: body mass index (BMI) is between 19 and 26 kg/m2(inclusive), and weight of no&#xD;
             less than 50 kg&#xD;
&#xD;
          4. Subjects who are willing to sign Informed Consent Form&#xD;
&#xD;
          5. Subjects should be able to communicate well with the investigator and be able to&#xD;
             complete the study in accordance with the protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -&#xD;
&#xD;
        Examinations:&#xD;
&#xD;
          1. Any abnormal and clinically significant findings to physical examination, vital sign,&#xD;
             routine laboratory tests (such as hematology, blood chemistry, blood coagulation&#xD;
             function, urinalysis, fecal occult blood), thyroid function test, 12-lead ECG, chest&#xD;
             CT, abdominal B-ultrasonography (liver, gallbladder, pancreas, spleen and kidney) and&#xD;
             so on&#xD;
&#xD;
          2. Heart rate at screening period &lt; 60 bpm, or 12-lead ECG QTcF ≥450 msec&#xD;
&#xD;
          3. Anyone has positive examination result of HBsAg/HBeAg, HCV antibody, HIV antibody and&#xD;
             treponema pallidum antibody&#xD;
&#xD;
          4. Screening for novel coronavirus infection: clinically significant abnormity of&#xD;
             C-reactive protein, or positive novel coronavirus nucleic acid&#xD;
&#xD;
             Medication history:&#xD;
&#xD;
          5. Use of any drug that inhibits or induces the function of hepatic drug-metabolizing&#xD;
             enzymes within 30 days prior to screening (see Appendix 1)&#xD;
&#xD;
          6. Use of any prescription drugs, over-the-counter drugs, Chinese herbal medicines or&#xD;
             food supplement such as vitamins, calcium supplement within 14 days prior to Screening&#xD;
&#xD;
          7. Use of any investigational drug within 3 months, or the drug withdrawal is less than 6&#xD;
             half-lives (whichever is longer) prior to successful enrollment for dosing&#xD;
&#xD;
             Medical history and surgery history:&#xD;
&#xD;
          8. Any history of clinically serious disease, or presence of illness/condition that the&#xD;
             investigator considers would affect the study results, including but not limited to&#xD;
             the diseases of circulatory system, respiratory system, endocrine system, nervous&#xD;
             system, digestive system, urinary system or history of blood, immune, mental and&#xD;
             metabolic diseases&#xD;
&#xD;
          9. History of organic heart disease, heart failure, myocardial infarction, angina&#xD;
             pectoris, unexplained arrhythmia, torsade ventricular tachycardia, ventricular&#xD;
             tachycardia, AV block, QT prolongation syndrome, or QT prolongation symptoms and&#xD;
             family history, indicated by genetic evidence or sudden death of a close relative due&#xD;
             to cardiac conditions at a young age&#xD;
&#xD;
         10. Major surgery history or surgical incision does not completely heal within 6 months&#xD;
             prior to the screening; Major surgery includes, but is not limited to, any subject&#xD;
             with significant bleeding risk, prolonged general anesthesia, incision of a biopsy or&#xD;
             significant traumatic injury&#xD;
&#xD;
         11. Allergic constitution, such as a known history of allergies to two or more substances;&#xD;
             or may be allergic to the investigational product or its excipients based on the&#xD;
             investigator's judgment&#xD;
&#xD;
         12. Suffering haemorrhoids or perianal disease with blood in the stool or regularly,&#xD;
             irritable bowel syndrome, inflammatory bowel disease&#xD;
&#xD;
             Life style:&#xD;
&#xD;
         13. Subjects have habitual constipation or diarrhoea&#xD;
&#xD;
         14. Subjects are alcoholism, or frequent alcohol consumption within six months prior to&#xD;
             screening, which means drinking more than 14 units of alcohol every week (one unit&#xD;
             alcohol equals 360 mL of beer, 45 mL of 40% alcohol or 150 mL of wine); or the alcohol&#xD;
             breath test result is ≥20 mg/dl in screening&#xD;
&#xD;
         15. Subjects have smoked more than 5 cigarettes per day in three months before screening,&#xD;
             or habitual use of nicotine products, and who can not quit smoking during the study&#xD;
&#xD;
         16. Abusing drug, using soft drugs such as marijuana three months prior to screening, or&#xD;
             using hard drugs such as cocaine, amphetamine, phencyclidine, etc. one year prior to&#xD;
             screening; or urine test for drugs is positive at screening&#xD;
&#xD;
         17. Subjects have habitual drinking of grapefruit juice, excessive tea, coffee and/or&#xD;
             caffeinated beverages, and who can not be abstained during the study&#xD;
&#xD;
             Others:&#xD;
&#xD;
         18. Subjects who have to work in radioactive conditions in long time, participated in&#xD;
             radio-labeled drug clinical study or had significant radioactive exposure within one&#xD;
             year before the study, no less than 2 times of chest/abdominal CT, or no less than 3&#xD;
             times of different types of X-ray exam&#xD;
&#xD;
         19. Subjects with a history of fear of needles, hemophobia, difficulty in blood collection&#xD;
             or inability to tolerate venipuncture blood collection;&#xD;
&#xD;
         20. Subjects who plan to have children or donate sperm during the study period and within&#xD;
             1 year after completion of the study, or those who disagree to take strict&#xD;
             contraceptive measures during the study or within 1 year after completion of the study&#xD;
             for themselves or their spouses (see Appendix 3 for details)&#xD;
&#xD;
         21. Subjects who received any vaccine within 4 weeks before screening, or plan to receive&#xD;
             the vaccine during the study&#xD;
&#xD;
         22. Subjects, who have had blood loss/donation up to 400 mL within 3 months, or received&#xD;
             blood transfusion within 1 month prior to screening&#xD;
&#xD;
         23. Subjects determined by the investigators to be unsuitable for participating in this&#xD;
             study for any reasons&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suzhou Connect</last_name>
    <role>Study Director</role>
    <affiliation>Suzhou Connect Biopharmaceuticals, Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tian Zhang</last_name>
    <phone>(+86)0512-53577866</phone>
    <email>tzhang@connectpharm.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Connect Investigative Site</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 2, 2021</study_first_submitted>
  <study_first_submitted_qc>September 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2021</study_first_posted>
  <last_update_submitted>September 10, 2021</last_update_submitted>
  <last_update_submitted_qc>September 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

